Please provide your email address to receive an email when new articles are posted on . Patients with severe glaucoma were more likely to experience steroid-induced ocular hypertension. Steroid ...
NDA submissions for NCX 470 are planned for the first half of 2026 in the US, with China following shortly after. NCX 470 is ...
Only about a quarter of patients with ocular hypertension lose peripheral vision, so clinicians should not recommend treatment to everyone with this condition, a long-term study suggests. The 20-year ...
USA: A large retrospective cohort study found that the dual GIP/GLP-1 receptor agonist tirzepatide was associated with a ...
DEDHAM, Mass.--(BUSINESS WIRE)--Qlaris Bio, Inc., a clinical-stage biotechnology company targeting unmet needs in debilitating ophthalmic diseases, today announced positive topline results from two ...
One of the world's leading causes of irreversible vision loss could begin with elevated eye pressure, according to a recent study published in Ophthalmology Science. Yi Hua, a biomedical engineering ...
MedPage Today on MSN
One GLP-1 drug may be better than rivals for glaucoma risk
In matched cohorts of more than 41,000 patients each, use of tirzepatide was linked to a significantly reduced risk of ...
Between February 1994 and October 1996, 3,328 individuals were considered for the study enrollment and 1,636 individuals met the requirements for the study. Recruitment was extended from 24 months to ...
GENEVA--(BUSINESS WIRE)--Alcon (SIX/NYSE: ALC), the global leader in eye care, dedicated to helping people see brilliantly, announced today the full U.S. commercial availability of Voyager ™ DSLT, the ...
Barnet Dulaney Perkins performs revolutionary, micro-invasive, injectable treatment for the full range of glaucoma disease to significantly decrease the dependence of daily eye drops. More than 3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback